Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?

INTERNATIONAL JOURNAL OF CARDIOLOGY

卷:321

Review

Volpe, Massimo^1,2  Battistoni, Allegra¹ 

[1] Sapienza Univ Rome, Fac Med & Psychol, Dept Clin & Mol Med, Rome, Italy

[2] IRCCS Neuromed, Pozzilli, Italy

关键词: Hypertension;    Covid-19;    Renin-angiotensin-aldosterone system;    Angiotensin-converting enzyme inhibitors;    Angiotensin receptor blockers;   

DOI  :  10.1016/j.ijcard.2020.07.041

来源: Elsevier

【 摘 要 】

A role for the renin-angiotensin-aldosterone-systemin Severe Acute Respiratory Syndrome-Coronavirus-2 infection and in the development of COronaVIrus Disease-19 disease has generated remarkable concerns among physicians and patients. Even though a suggestive pathophysiological link between renin-angiotensin-aldosteronesystemand the virus has been proposed, its pathogenic role remains very difficult to be defined. Although COrona VIrus Disease-19 targets preferentially older peoplewith high prevalence of hypertension and extensive use of renin-angiotensin-aldosterone-system inhibitors, an independent role for hypertension and its therapies is not defined. In this article, we scrutinize evidence from themost representative available studies inwhich the potential role of renin-angiotensin systeminhibitors, specifically angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, was evaluated in the COronaVIrus Disease-19 disease course, with regard to severity of the disease and mortality. We conclude that at this time, the overall available evidence fails to support a pathogenetic speaks against any harmful role for of renin-angiotensin-aldosterone-system inhibitors in COronaVIrus Disease-19. Consequently, we conclude that treatment with renin-angiotensin-aldosterone-system inhibitors should not be discontinued and, therefore, these therapies should not be interrupted. (C) 2020 Elsevier B.V. All rights reserved.

【 授权许可】

Free